Celularity Inc. Class A Common Stock CELU
i
Market dataready · fetched 2026-11-11T14:55:36.858Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:52:19.225178951Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-11T14:53:11.276303+00:00
Celularity Inc. Class A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 4.91 | 800.0% | 618.0% | 0.53 | 772.8% | 78.3% |
| 25Δ | 4.31 | 800.0% | 536.0% | 0.60 | 721.7% | 69.5% |
| 30Δ | 3.71 | 800.0% | 454.0% | 0.67 | 670.7% | 60.6% |
| 35Δ | 3.10 | 800.0% | 372.1% | 0.73 | 619.6% | 51.8% |
| 40Δ | 2.50 | 800.0% | 290.1% | 0.80 | 568.6% | 42.9% |
| 45Δ | 0.86 | 517.5% | 34.1% | |||
| 50Δ | 1.00 | 488.6% | 55.9% | 0.93 | 466.5% | 25.2% |
| 55Δ | 0.92 | 512.9% | 50.0% | 0.99 | 415.4% | 16.4% |
| 60Δ | 0.84 | 537.2% | 44.1% | 1.06 | 393.9% | 13.5% |
| 65Δ | 0.76 | 561.5% | 38.1% | 1.14 | 377.1% | 11.5% |
| 70Δ | 0.68 | 585.8% | 32.2% | 1.21 | 360.4% | 9.5% |
| 75Δ | 0.60 | 610.1% | 26.3% | 1.28 | 343.7% | 7.5% |
| 80Δ | 0.52 | 634.4% | 20.3% | 1.35 | 326.9% | 5.6% |
20Δ
- Pseudo strike
- 4.91
- IV
- 800.0%
- B/E move
- 618.0%
- Pseudo strike
- 0.53
- IV
- 772.8%
- B/E move
- 78.3%
25Δ
- Pseudo strike
- 4.31
- IV
- 800.0%
- B/E move
- 536.0%
- Pseudo strike
- 0.60
- IV
- 721.7%
- B/E move
- 69.5%
30Δ
- Pseudo strike
- 3.71
- IV
- 800.0%
- B/E move
- 454.0%
- Pseudo strike
- 0.67
- IV
- 670.7%
- B/E move
- 60.6%
35Δ
- Pseudo strike
- 3.10
- IV
- 800.0%
- B/E move
- 372.1%
- Pseudo strike
- 0.73
- IV
- 619.6%
- B/E move
- 51.8%
40Δ
- Pseudo strike
- 2.50
- IV
- 800.0%
- B/E move
- 290.1%
- Pseudo strike
- 0.80
- IV
- 568.6%
- B/E move
- 42.9%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.86
- IV
- 517.5%
- B/E move
- 34.1%
50Δ
- Pseudo strike
- 1.00
- IV
- 488.6%
- B/E move
- 55.9%
- Pseudo strike
- 0.93
- IV
- 466.5%
- B/E move
- 25.2%
55Δ
- Pseudo strike
- 0.92
- IV
- 512.9%
- B/E move
- 50.0%
- Pseudo strike
- 0.99
- IV
- 415.4%
- B/E move
- 16.4%
60Δ
- Pseudo strike
- 0.84
- IV
- 537.2%
- B/E move
- 44.1%
- Pseudo strike
- 1.06
- IV
- 393.9%
- B/E move
- 13.5%
65Δ
- Pseudo strike
- 0.76
- IV
- 561.5%
- B/E move
- 38.1%
- Pseudo strike
- 1.14
- IV
- 377.1%
- B/E move
- 11.5%
70Δ
- Pseudo strike
- 0.68
- IV
- 585.8%
- B/E move
- 32.2%
- Pseudo strike
- 1.21
- IV
- 360.4%
- B/E move
- 9.5%
75Δ
- Pseudo strike
- 0.60
- IV
- 610.1%
- B/E move
- 26.3%
- Pseudo strike
- 1.28
- IV
- 343.7%
- B/E move
- 7.5%
80Δ
- Pseudo strike
- 0.52
- IV
- 634.4%
- B/E move
- 20.3%
- Pseudo strike
- 1.35
- IV
- 326.9%
- B/E move
- 5.6%
Options history
No recorded observations
Biotechnology
CGEM
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United…
More →CGON
CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus…
More →CHRS
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in…
More →CING
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders.…
More →CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.…
More →CLYM
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. The company is headquartered in Wilmington, Delaware.
More →